Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial
Authors:
- 1 December 2020
- journal article
- research article
- Published by Elsevier in The Lancet Haematology
- Vol. 7 (12) , e874-e883
Abstract
No abstract availableKeywords
Funding Information
- Celgene
- Takeda Pharmaceutical Company
- Janssen Research and Development
- Janssen Pharmaceutica
This publication has 19 references indexed in Scilit:
- Frontline therapy of multiple myelomaBlood, 2015
- European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myelomaHaematologica, 2014
- Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantCancer, 2013
- Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaLeukemia, 2013
- Responsiveness and minimal important score differences in quality‐of‐life questionnaires: a comparison of the EORTC QLQ‐C30 cancer‐specific questionnaire to the generic utility questionnaires EQ‐5D and 15D in patients with multiple myelomaEuropean Journal of Haematology, 2011
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 studyThe Lancet, 2010
- Estimation of minimally important differences in EQ-5D utility and VAS scores in cancerHealth and Quality of Life Outcomes, 2007
- A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive functionCancer, 2005
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990